PharVision Advisers’s Avient AVNT Stock Holding History

PharVision Advisers’s Portfolio AVNT Stock Details AVNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-7,278	Closed	-$240K	–	701
2025 Q3	$240K	Buy	+7,278	New	+$253K	0.13%	360

Other funds holding AVNT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CCM

Channing Capital Management Chicago, Illinois $3.91B AUM 34.32% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

PharVision Advisers's AVNT Position: Q4 2025 in Review

PharVision Advisers sold out of Avient (AVNT) in Q4 2025, closing a stake of 7,278 shares — an estimated $240K sold.

PharVision Advisers first reported a position in AVNT in Q3 2025 and held it in 1 quarter. The position peaked at $240K in Q3 2025. 318 funds tracked by Wall St. Rank hold AVNT as of Q4 2025.

PharVision Advisers reported no remaining Avient position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 7,278 Avient shares in Q4 2025, an estimated $240K.
PharVision Advisers first reported a position in Avient in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Avient position peaked at $240K in Q3 2025.
318 funds tracked by Wall St. Rank held Avient as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.